All Shire articles
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
BusinessTakeda set to swallow Shire
Shire’s US revenue and rare diseases portfolio grab Japanese firm’s attention
-
BusinessDementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
-
Business
Shire to buy rare disease specialist Dyax
Deal includes an already-approved drug for angioedema and an experimental antibody treatment
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Shire makes hostile bid for Baxalta
Recently spun-out from Baxter, Baxalta is resisting the deal, saying it wants time to prove its true value
-
Business
Mergers and moves trigger pharma layoffs
Shire expects to sack 500 or more employees, while Merck and GSK also wield the axe
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
Business
Shire deepens rare disease focus with NPS buyout
Approval of parathyroid hormone drug further validates acquisition decision
-
-
Business
AbbVie backs out of Shire deal
Treasury rule changes make inversion ‘too uncertain’ and remove financial benefits
-
BusinessPharma firms rush to escape US tax shackles
AbbVie–Shire and Mylan–Abbott mergers both allow US firms to escape to lower-tax European countries
-
Business
Shire fends off AbbVie takeover bid
Board says deal undervalues the company and its growth potential
-
Business
Shire will cut UK R&D to focus on rare diseases
$4.2bn buyout of ViroPharma bolsters pipeline, while Basingstoke site halts research